Eligibility for Posthospitalization Venous Thromboembolism Prophylaxis in Hospitalized Patients With COVID‐19: A Retrospective Cohort Study

BACKGROUND: A recent randomized trial, the MICHELLE trial, demonstrated improved posthospital outcomes with a 35‐day course of prophylactic rivaroxaban for patients hospitalized with COVID‐19 at high risk of venous thromboembolism. We explored how often these findings may apply to an unselected clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaughn, Valerie M., Ratz, David, McLaughlin, Elizabeth S., Horowitz, Jennifer K., Flanders, Scott A., Middleton, Elizabeth A., Grant, Paul J., Kaatz, Scott, Barnes, Geoffrey D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673710/
https://www.ncbi.nlm.nih.gov/pubmed/36073649
http://dx.doi.org/10.1161/JAHA.122.025914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673710/
https://www.ncbi.nlm.nih.gov/pubmed/36073649
http://dx.doi.org/10.1161/JAHA.122.025914

Ejemplares similares